Hepatitis C  |  NASH


​FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARAMACIES WITHOUT BIAS.  

Data Elements


DEMOGRAPHICS

  • Diagnosis
  • Age
  • Gender
  • Race / Ethnicity
  • BMI
  • Height / Weight
  • Genotype
  • Fibrosis Score

LABS

  • CBC
  • HDL
  • ALT / AST
  • HCV Viral Load
  • Platelets
  • Serum Creatinine
  • eGFR
  • HbA1C
  • SVR12 Outcome

PRIOR HISTORY

  • Prior Treatment Status
  • Prior Treatment Regimen
  • Duration of Therapy
  • Reason for Failure
  • Prior Transplant
  • Smoking Status
  • Illicit Drug Use

COMORBIDS

  • HIV Coinfection
  • Anxiety
  • Depression
  • Hypertension
  • Diabetes
  • Chronic Kidney Disease
  • Hyperlipidemia
  • Hemodialysis

PROVIDERS

  • Type (Physician, NP, PA)
  • Specialty
  • Academic vs Community
  • Specialty Pharmacy

PAYERS

  • Type (Commercial, Medicare, Medicaid, Dual Eligible)
  • Payer Name
  • Self-Pay and Patient Assistance
  • Eligibility
  • Correct PA form
  • Denial Reason

PA TIMELINE

  • Copay Amount
  • PA Submitted Date
  • Approval / Denial Date
  • Appeals Submitted

DISPENSING INFO

  • Current Treatment Regimen Rx
  • Intended Regimen
  • Actual Regimen
  • Duration
  • Dispensed Regimen
  • Gaps in Therapy

HCV Scientific Steering Committee


Trio’s unbiased insights have established a high level of integrity based on the Scientific Steering Committee expertise, diversity, and credibility to deliver transparent insight on the disease.

Nezam Afdhal, MD

  • Chairman – HCV Steering Committee
  • Professor of Medicine, Harvard Medical School
  • Beth Israel Deaconess Hospital (BIDMC) Boston, MA

Bruce Bacon, MD

  • James F. King, MD Endowed Chair in Gastroenterology at Saint Louis University (SLU), St. Louis, MO
  • Former President of the AASLD in 2004
  • Chair of the AASLD Foundation since 2013

Michael Curry, MD

  • Section Chief, Director of Liver Transplant, BIDMC, Boston MA
  • Associate Professor, Medicine, Harvard Medical School

Steven Flamm, MD

  • Professor of Medicine & Surgery, Division of Hepatology at Northwestern University, Chicago, IL
  • Chief of Transplantation Hepatology
  • Trustee of the AASLD Foundation

Naoky Tsai, MD

  • Private Practice – Honolulu, HI
  • Professor of Medicine – University of Hawaii

Zobair Younossi, MD, MPH

  • Chairman, Department of Medicine, Inova Fairfax Hospital, Fairfax, VA
  • Professor of Medicine, Virginia Commonwealth University
  • Chair of the Medical Advisory Committee of the National Capital Chapter of the ALF

COMMITTEE MEMBER ACCOMPLISHMENTS


Publication
Journals

  • Annals of Internal Medicine
  • APS - American Physiological Society
  • Clinical Gastroenterology
  • Journal of Hepatology
  • World Journal of Gastroenterology
  • The New England Journal of Medicine
  • Liver International

Associations
and Foundations

  • AASLD Foundation
  • American Board of Internal Medicine
  • ACG
  • ACP
  • AGA
  • American Liver Foundation
  • Hepatitis B Foundation
  • EASL
  • NIH

Advisory Board
Affiliations

  • AbbVie
  • AEVI
  • Angion
  • Bristol-Myers Squibb
  • Gilead
  • Ligand
  • Merck
  • Salix
  • Spring Bank

Publications & Abstracts


2019


Access to HCV Cure Under Medicaid Programs in the United States

Zobair Younossi, Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Janna Radtchenko, Naoky Tsai and Nezam Afdhal

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019

Conference dates: May 18, 2019 - May 22, 2019


Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging

Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi and Nezam Afdhal

Oral Presented at: Digestive Disease Week (DDW)

Conference dates: April 10, 2019 - April 14, 2019


Effectiveness of the Salvage Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Chronic Hepatitis C; Clinical Practice Experience from the Trio Network

Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019


Clinical Practice Experience with Pangenotypic Therapies Glecaprevir-Pibrentasvir and Sofosbuvir-Velpatasvir; Data from the Trio Network

Michael Curry, Bruce Bacon, Steven L Flamm, Nicole Wick, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019


Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging

Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019


Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US

Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Janna Radtchenko, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Jason Gillman, Karam Mounzer and Rick Elion

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019




2018


Change in Demographics of Direct-Acting Antiviral (DAA)-Prescribed HCV Patients from 2013 to 2018: Data from 19,994 Patients in the TRIO Network

Naoky Tsai, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Zobair Younossi and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018


Effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) for Treatment Naïve, Non-Cirrhotic Patients with HCV Infection in the TRIO Health Network

Steven L. Flamm, Jens Kort, Steve Marx, John Strezewski, Bruce Bacon, Michael P. Curry, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018


Preferences and Outcomes in Clinical Practice with Glecaprevir/Pibrentasvir (GLE-PIB), Ledipasvir/Sofosbuvir (LDV-SOF), and Sofosbuvir/Velpatasvir (SOF-VEL): Data from the TRIO Network

Michael Curry, Bruce Bacon, Steven L. Flamm, Michael Marks, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018


Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Care of Chronic Hepatitis C Patients: Clinical Practice Experience from the TRIO Network

Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018


Disparities in Accessing HCV Care Under Medicaid Programs Across the US: Experience from the TRIO Network

Zobair Younossi, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Naoky Tsai and Nezam Afdhal

Oral Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018


Realized Durations of Direct-Acting Antivirals (DAAs) in Care of HCV in US Clinical Practice: Data from the Trio Network

Michael Curry, Bruce Bacon, Steven Flamm, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal

Poster Presented at: Global Hepatitis Summit (GHS)

Conference dates: June 14, 2018 - June 17, 2018


Behavioral and Clinical Factors and Direct Acting Antiviral (DAA) Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Rick Elion, Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles and Karam Mounzer

Oral Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018


Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018


Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018


Access to and Utilization of Sofosbuvir/Velpatasvir/Voxilaprevir in Care of Chronic Hepatitis C Patients: Data from the TRIO Network

Bruce Bacon, Michael Curry, Steven Flamm, John Straub, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018


Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load <6mm IU/ml: Analyses of Real-World Data from the TRIO Network

Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018


Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network

Dushwantha Jayaweera, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer and Rick Elion

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018


Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the TRIO Network

Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018


Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network

Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer and Rick Elion

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018


Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018


Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018


Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 11, 2018 - April 15, 2018


2018

Changing Demographics Among Prescribed Hepatitis C Populations, 2013-2017

Use of Elbasvir-Grazoprevir in Patients With Chronic Hepatitis C and Chronic Kidney Disease (CKD): Retrospective Analyses from Clinical Practice

Real-World Use of Elbasvir-Grazoprevir in Patients with Chronic Hepatitis C: Retrospective Analyses From the TRIO Network

The impact of individual patient data in a network meta-analysis: An investigation into parameter estimation and model selection



2017


Real-World Patterns of Therapy Utilization and Outcomes in 8,049 HCV Patients: Data from the TRIO Network

Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017


Drivers of Therapy Choice in Genotype 1 HCV: Analyses of Real-World Data from the TRIO Network

M. Curry, B. Bacon, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi and N. Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017


HCV Treatment Failure in the Era of Direct-Acting Antivirals (DAAs): Analyses of Real-World Data from the TRIO Network

Bruce Bacon, Steven L. Flamm, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017


Cure Denied and Cure Delayed in Chronic Hepatitis C; Monitoring Non-Start Rates and Increased Time to Start Using Real-World Data from the TRIO Network

Zobair Younossi, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017


Impact of Treatment Duration and Ribavirin (RBV) Addition on Real-World Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Select Patient Subgroups with Genotype 1 (GT1) Chronic Hepatitis C (HCV): Retrospective Data Analyses from the TRIO Network

C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi and N. Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017


Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Treatment Naïve (TN) Genotype 1a (GT1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A Resistance-Associated Substitutions (RASs)

C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi and N. Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: October 20, 2017 - October 24, 2017


Real-World Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network

Flamm SL, Bacon BR, Curry MP, Dieterich DT, Kowdley KV, Milligan S, Tsai NC, Younossi ZM and Afdhal NH

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 6, 2017 - May 9, 2017


Sofosbuvir/Velpatasvir in Genotype 2-6 HCV: Real-World Experience from the TRIO Network

Curry MP, Bacon BR, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Tsai NC, Younossi ZM and Afdhal NH

Oral Presented at: Digestive Disease Week (DDW)

Conference dates: May 6, 2017 - May 9, 2017


Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network

Tsai NC, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Younossi ZM and Afdhal NH

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 6, 2017 - May 9, 2017


Access to HCV Care for 31,154 Patients in the United States: Real-World Experience from the TRIO Network

Younossi ZM, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Tsai NC and Afdhal NH

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 6, 2017 - May 9, 2017


Real-World Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network

Flamm SL, Bacon B, Curry MP, Dieterich DT, Kowdley KV, Milligan S, Tsai NC, Younossi ZM and Afdhal NH

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017


Utilization of Sofosbuvir/Velpatasvir in Genotype 2-6 HCV: Real-World Experience from the TRIO Network

Tsai NC, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Younossi ZM and Afdhal NH

Oral Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017


Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network

Tsai NC, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Younossi ZM and Afdhal NH

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017


Real-World Use of Elbasvir/Grazoprevir and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data Analyses from the TRIO Network

Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Nwankwo C, Tsai NC, Younossi ZM and Afdhal NH

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017


Elbasvir/Grazoprevir Effectiveness in Patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-World Experience from the TRIO Network

Younossi ZM, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdley KV, Milligan S, Nwankwo C, Tsai NC, and Afdhal NH

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 13, 2017 - April 17, 2017




2016


Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network

Korenblat K, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Kowdle KV, Lee Y, Tsai NH, Younossi ZM and Afdhal NH

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 11, 2016 - November 15, 2016


Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network

Afdhal NH, Bacon BR, Curry MP, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC and Younossi ZM

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 21, 2016 - May 24, 2016


Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience From the Trio Network

Kevin Korenblat, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven Flamm, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: May 21, 2016 - May 24, 2016


2016

No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/ Sofosbuvir (LDV/SOF): Real-World Data from 2,034 Genotype 1 Patients In the TRIO Network

Real-World Use of Elbasvir/Grazoprevir and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data Analyses from the TRIO Network

Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network

Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV Viral Load (VL) <6 million IU/ml; A Comparative Analysis of the Phase-3 ION-3 Data to Real-World Effectiveness

Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network                

Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment Naïve (TN) Genotype 1a (G1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A resistance-associated substitutions (RASs)  

Evaluation of Efficacy of Ledipasvir/Sofosbuvir for 12 weeks in a Real-Life Population of Genotype 1a and 1b HCV Patients: Data from the TRIO Network

2015

Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network        

Efficacy Evaluation of 24-week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network

Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients over 70 years; Data from the TRIO Network 

Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network                

Final Evaluation of HCV Patients Treated with 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

Evaluation of Access to Care in Patients Prescribed Sofosbuvir-containing Regimens; Data from the TRIO Network

Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network

Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network 

2014

Evaluation of Efficacy of Sofosbuvir and Simeprevir-based Regimens in a Real-Life Population of HCV Patients with Cirrhosis; Data from the TRIO Network     

Efficacy of Sofosbuvir and Simeprevir-based Regimens for HCV Treatment-Experienced GT1 Patients in a Real-Life Setting; Data from the TRIO Network